SG11201808402RA - Methods of treatment for cholestatic and fibrotic diseases - Google Patents
Methods of treatment for cholestatic and fibrotic diseasesInfo
- Publication number
- SG11201808402RA SG11201808402RA SG11201808402RA SG11201808402RA SG11201808402RA SG 11201808402R A SG11201808402R A SG 11201808402RA SG 11201808402R A SG11201808402R A SG 11201808402RA SG 11201808402R A SG11201808402R A SG 11201808402RA SG 11201808402R A SG11201808402R A SG 11201808402RA
- Authority
- SG
- Singapore
- Prior art keywords
- cholestatic
- treatment
- methods
- fibrotic diseases
- fibrotic
- Prior art date
Links
- 230000001587 cholestatic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000003176 fibrotic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305425 | 2016-04-11 | ||
| PCT/EP2017/055878 WO2017178172A1 (en) | 2016-04-11 | 2017-03-13 | Methods of treatment for cholestatic and fibrotic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808402RA true SG11201808402RA (en) | 2018-10-30 |
Family
ID=55755536
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808402RA SG11201808402RA (en) | 2016-04-11 | 2017-03-13 | Methods of treatment for cholestatic and fibrotic diseases |
| SG10202004425XA SG10202004425XA (en) | 2016-04-11 | 2017-03-13 | Methods of treatment for cholestatic and fibrotic diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202004425XA SG10202004425XA (en) | 2016-04-11 | 2017-03-13 | Methods of treatment for cholestatic and fibrotic diseases |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US20170290812A1 (en) |
| EP (3) | EP3442580B1 (en) |
| JP (1) | JP6894923B2 (en) |
| KR (1) | KR102431257B1 (en) |
| CN (1) | CN109069648B (en) |
| AU (1) | AU2017249602B2 (en) |
| CA (1) | CA3019399A1 (en) |
| DK (2) | DK3442580T3 (en) |
| EA (2) | EA201892298A1 (en) |
| ES (3) | ES2935185T3 (en) |
| HR (1) | HRP20201954T1 (en) |
| HU (2) | HUE052886T2 (en) |
| IL (1) | IL262052B (en) |
| LT (1) | LT3442580T (en) |
| MD (1) | MD3442580T2 (en) |
| MX (1) | MX384261B (en) |
| MY (1) | MY195437A (en) |
| PH (1) | PH12018502142B1 (en) |
| PL (1) | PL3442580T3 (en) |
| PT (2) | PT3442580T (en) |
| SG (2) | SG11201808402RA (en) |
| SI (1) | SI3442580T1 (en) |
| WO (1) | WO2017178172A1 (en) |
| ZA (1) | ZA201807389B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019513762A (en) * | 2016-04-11 | 2019-05-30 | ジェンフィＧｅｎｆｉｔ | Method of treating cholestasis and fibrosis |
| SG11201808402RA (en) | 2016-04-11 | 2018-10-30 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| CA3054103A1 (en) | 2017-03-13 | 2018-09-20 | Genfit | Pharmaceutical compositions for combination therapy |
| CA3057284A1 (en) * | 2017-03-21 | 2018-09-27 | Novalead Pharma Inc. | Therapeutic agent for phosphodiesterase inhibition and its related disorders |
| EP3709985A1 (en) * | 2017-11-17 | 2020-09-23 | Köster, Hubert | [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate for use in lymphangioleiomyomatosis and other diseases |
| EP3639822A1 (en) * | 2018-10-15 | 2020-04-22 | Universität Regensburg | Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion |
| US12458612B2 (en) | 2019-04-10 | 2025-11-04 | Genfit | Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists |
| JP2022528727A (en) * | 2019-04-12 | 2022-06-15 | ジェンフィット | Nitazoxanide and thiazolide for use in the treatment of diseases associated with oxidative stress |
| CN110205302B (en) * | 2019-06-24 | 2021-03-23 | 扬州大学 | Cell strain secreting monoclonal antibody against mycophenolic acid, monoclonal antibody and application thereof |
| CN110478357A (en) * | 2019-07-23 | 2019-11-22 | 哈尔滨医科大学 | The application of Nitazoxanide and its cylinder metabolism-ure in anti-obesity, reducing blood lipid, anti-fatty liver and antiatherosclerosis |
| CN110368498A (en) * | 2019-08-26 | 2019-10-25 | 瑞希(重庆)生物科技有限公司 | A kind of preparation and preparation method thereof promoting wound healing |
| AU2020376223A1 (en) | 2019-10-28 | 2022-06-02 | Genfit | Combination therapy having antioxydant properties |
| CN113398125B (en) * | 2020-03-16 | 2024-05-03 | 绍兴君科臻元医药科技有限公司 | Tizoxanide pharmaceutical composition and medical use thereof |
| WO2022106425A1 (en) * | 2020-11-17 | 2022-05-27 | Genfit | Methods of treatment of liver failure |
| CN116507343A (en) * | 2020-11-17 | 2023-07-28 | 基恩菲特公司 | ways to treat liver failure |
| WO2022218239A1 (en) * | 2021-04-12 | 2022-10-20 | 杜心赟 | New-type thiazole compound, preparation method therefor and use thereof |
| WO2023078435A1 (en) * | 2021-11-05 | 2023-05-11 | 广州市妇女儿童医疗中心 | Application of folic acid in prevention, diagnosis, and treatment of hereditary, infectious, or allergic diseases |
| JP2025532357A (en) * | 2022-10-04 | 2025-09-29 | ジェンフィット | Nitazoxanide for the treatment of liver dysfunction |
| CN116911513B (en) * | 2023-02-07 | 2024-07-26 | 中国药科大学 | Application of nitazoxanide and its in vivo metabolite tizoxanide in the preparation of anti-heart failure drugs |
| WO2025063816A1 (en) * | 2023-09-21 | 2025-03-27 | 오토텔릭바이오 주식회사 | Composition for treating uterine fibrosis comprising thiazole derivative compound |
| CN117838690B (en) * | 2023-10-09 | 2024-09-13 | 中国药科大学 | Compound medicine for treating diseases taking AMPK activation as treatment target and application thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1437800A (en) | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
| GB1440212A (en) | 1973-08-29 | 1976-06-23 | Phavic Sprl | Derivatives of 2-phenoxyacetamido-5-nitrothiazoles |
| US5965590A (en) | 1994-09-08 | 1999-10-12 | Romark Lab Lc | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
| US5968961A (en) | 1997-05-07 | 1999-10-19 | Romark Laboratories, L.C. | Pharmaceutical compositions of tizoxanide and nitazoxanide |
| MX9604483A (en) | 1994-09-08 | 1998-02-28 | Jean-Francois Rossignol | Benzamide derivative, compositions containing said derivative and use thereof. |
| US5935591A (en) | 1998-01-15 | 1999-08-10 | Romark Laboratories, L.C. | Method for treatment of equine protozoal myeloencephalitis with thiazolides |
| US6114365A (en) | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| CA2436739A1 (en) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Combination agent |
| RU2006111093A (en) | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | MODULATORS OF ATR-BINDING CASSETTE TRANSPORTERS |
| UA90864C2 (en) | 2004-09-09 | 2010-06-10 | Ромарк Лебораториз, Л.К. | Halogenated benzamide derivatives |
| EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| EP1971594A2 (en) | 2005-11-21 | 2008-09-24 | Biogen Idec MA Inc. | Substituted pyrazalones |
| CA2636527C (en) * | 2006-01-09 | 2016-05-17 | Romark Laboratories, L.C. | Viral hepatitis treatment |
| US8455658B2 (en) | 2006-01-25 | 2013-06-04 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
| GB0619500D0 (en) | 2006-10-03 | 2006-11-08 | Univ Keele | Treatment of fibrosis |
| BRPI0815057B8 (en) | 2007-08-03 | 2021-05-25 | Romark Laboratories Lc | compound, pharmaceutical composition, and use of a compound |
| US20110177999A1 (en) * | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
| KR101045572B1 (en) | 2007-08-14 | 2011-07-01 | 주식회사 엘지화학 | Propionyl-CoA Transferase Variants Derived from Cructostilridium Substances and Processes for Producing Lactate Polymers or Lactate Copolymers Using the Variants |
| US9149463B2 (en) * | 2007-09-18 | 2015-10-06 | The Board Of Trustees Of The Leland Standford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
| JP5715820B2 (en) | 2007-09-18 | 2015-05-13 | スタンフォード ユニバーシティー | Methods for treating infections with Flaviviridae family viruses and compositions for treating infections with Flaviviridae family viruses |
| US20100016262A1 (en) | 2007-10-18 | 2010-01-21 | Yale University | Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis |
| EP2408449A4 (en) * | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
| EA021587B1 (en) | 2009-05-12 | 2015-07-30 | РОМАРК ЛЭБОРЕТЕРИЗ Эл. Си. | Haloalkyl heteroaryl benzamide compounds |
| EA030679B1 (en) | 2009-06-26 | 2018-09-28 | РОМАРК ЛЭБОРЕТЕРИЗ Эл.Си. | CONNECTIONS AND METHODS OF TREATING INFLUENZA |
| MX2012005601A (en) | 2009-11-16 | 2012-08-01 | Univ Georgia | 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections. |
| US8816074B2 (en) | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
| EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| WO2012027710A2 (en) | 2010-08-27 | 2012-03-01 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| WO2012061190A1 (en) | 2010-11-01 | 2012-05-10 | Romark Laboratories L.C. | Alkylsulfinyl-substituted thiazolide compounds |
| CN110152000A (en) | 2011-03-02 | 2019-08-23 | J·深塔格 | Composition for the treatment of hepatic steatosis alone or in the treatment of hepatic steatosis with hepatitis C virus infection |
| CN107096032A (en) | 2011-05-16 | 2017-08-29 | 罗马克实验室有限公司 | In the method for object moderate stimulation immune response in need |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2013202269A1 (en) * | 2011-10-26 | 2013-05-16 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
| WO2013082469A2 (en) | 2011-12-02 | 2013-06-06 | University Of Vermont And State Agricultural College | Methods and compositions for treating infections |
| US9750705B2 (en) | 2012-08-31 | 2017-09-05 | The Regents Of The University Of California | Agents useful for treating obesity, diabetes and related disorders |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9974767B2 (en) | 2014-07-14 | 2018-05-22 | University Of Washington | Statins in the treatment of muscular dystrophies and myopathies |
| BR112017009651A2 (en) | 2014-11-11 | 2017-12-19 | Romark Laboratories Lc | compound, pharmaceutical composition, and method for treating an intracellular protozoan infection, a viral infection or a cancer. |
| WO2016210247A1 (en) | 2015-06-24 | 2016-12-29 | Duke University | New methods of use for an anti-diarrhea agent |
| SG11201808402RA (en) | 2016-04-11 | 2018-10-30 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| KR102410951B1 (en) | 2016-04-11 | 2022-06-20 | 장피트 | Methods of treatment of cholestatic and fibrotic diseases |
| JP2019513762A (en) | 2016-04-11 | 2019-05-30 | ジェンフィＧｅｎｆｉｔ | Method of treating cholestasis and fibrosis |
-
2017
- 2017-03-13 SG SG11201808402RA patent/SG11201808402RA/en unknown
- 2017-03-13 ES ES20194458T patent/ES2935185T3/en active Active
- 2017-03-13 SG SG10202004425XA patent/SG10202004425XA/en unknown
- 2017-03-13 PL PL17710285T patent/PL3442580T3/en unknown
- 2017-03-13 EP EP17710285.2A patent/EP3442580B1/en active Active
- 2017-03-13 PT PT177102852T patent/PT3442580T/en unknown
- 2017-03-13 PT PT201944584T patent/PT3777855T/en unknown
- 2017-03-13 KR KR1020187032681A patent/KR102431257B1/en active Active
- 2017-03-13 MX MX2018012287A patent/MX384261B/en unknown
- 2017-03-13 WO PCT/EP2017/055878 patent/WO2017178172A1/en not_active Ceased
- 2017-03-13 ES ES20194454T patent/ES2928408T3/en active Active
- 2017-03-13 DK DK17710285.2T patent/DK3442580T3/en active
- 2017-03-13 EP EP20194458.4A patent/EP3777855B1/en active Active
- 2017-03-13 EA EA201892298A patent/EA201892298A1/en unknown
- 2017-03-13 MY MYPI2018001719A patent/MY195437A/en unknown
- 2017-03-13 HU HUE17710285A patent/HUE052886T2/en unknown
- 2017-03-13 EP EP20194454.3A patent/EP3777854B1/en active Active
- 2017-03-13 AU AU2017249602A patent/AU2017249602B2/en active Active
- 2017-03-13 MD MDE20190213T patent/MD3442580T2/en unknown
- 2017-03-13 US US15/457,158 patent/US20170290812A1/en not_active Abandoned
- 2017-03-13 HU HUE20194458A patent/HUE060671T2/en unknown
- 2017-03-13 LT LTEP17710285.2T patent/LT3442580T/en unknown
- 2017-03-13 EA EA202191466A patent/EA202191466A1/en unknown
- 2017-03-13 SI SI201730549T patent/SI3442580T1/en unknown
- 2017-03-13 DK DK20194458.4T patent/DK3777855T3/en active
- 2017-03-13 CA CA3019399A patent/CA3019399A1/en active Pending
- 2017-03-13 ES ES17710285T patent/ES2839453T3/en active Active
- 2017-03-13 CN CN201780023160.XA patent/CN109069648B/en active Active
- 2017-03-13 PH PH1/2018/502142A patent/PH12018502142B1/en unknown
- 2017-03-13 JP JP2018553102A patent/JP6894923B2/en active Active
- 2017-03-13 HR HRP20201954TT patent/HRP20201954T1/en unknown
- 2017-12-11 US US15/837,889 patent/US10130612B2/en active Active
- 2017-12-14 US US15/841,777 patent/US10117855B2/en active Active
- 2017-12-14 US US15/841,981 patent/US10117856B2/en active Active
- 2017-12-14 US US15/842,234 patent/US10130613B2/en active Active
-
2018
- 2018-09-19 US US16/135,945 patent/US20190000813A1/en not_active Abandoned
- 2018-10-02 IL IL262052A patent/IL262052B/en unknown
- 2018-11-05 ZA ZA2018/07389A patent/ZA201807389B/en unknown
-
2020
- 2020-06-24 US US16/910,756 patent/US11103484B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807389B (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| ZA202006746B (en) | Methods of treatment | |
| IL253244A0 (en) | Methods of treating retinal diseases | |
| ZA201807390B (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| HUS2500033I1 (en) | Treatment of intrahepatic cholestatic diseases | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| IL274541A (en) | Method of treatment of gastrointestinal diseases with tradipitant | |
| ZA201705877B (en) | Method of treating diseases | |
| ZA201808360B (en) | Treatment of intrahepatic cholestatic diseases | |
| GB201416832D0 (en) | Methods of treatment | |
| IL253847A0 (en) | Methods of treating diseases | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| GB201602802D0 (en) | Method of treatment | |
| EP3151824A4 (en) | Methods of treating neurodevelopmental diseases and disorders | |
| HK40001765A (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| GB201500555D0 (en) | Method and device for the treatment of diseases | |
| EP3193935A4 (en) | Treatment of fibrotic diseases | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201801249D0 (en) | Methods of treatment | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer | |
| AU2014902173A0 (en) | Methods of treating neurodevelopmental diseases and disorders | |
| GB201414023D0 (en) | Treatment of autoimmune diseases | |
| GB201421511D0 (en) | Methods of screening and treatment |